Clinical Trial Detail

NCT ID NCT01484041
Title Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
Recruitment Terminated
Gender female
Phase Phase Ib/II
Variant Requirements yes
Sponsors Georgetown University|Novartis Pharmaceuticals
Indications

Her2-receptor negative breast cancer

Therapies

Dovitinib

Age Groups: adult

Additional content available in CKB BOOST